Focusing on restoring the man-microbiota symbiosis using a unique breakthrough technology – the autologous fecal microbiotherapy – MaaT Pharma is celebrating its first anniversary One year of success for MaaT Pharma.
- MaaT Pharma and Lutech Sign Licensing Agreement on Microbiome Therapy for Graft-vs-Host Disease
- MaaT Pharma Launches European Clinical Trial in Severe Acute Graft-versus-Host Disease for patients receiving allogeneic Hematopoietic Stem Cell Transplantation
- Hervé Affagard on Europe1 Label Entreprise
- Dr. Joël Doré, MaaT Pharma’s co-founder, received awards for his work
- MaaT Pharma To Release First in Patients Data At The 2017 ASH Meeting On Autologous Fecal Microbiota Transfer And Restoration Of Microbiota Diversity